{"entity":{"id":"nct05669430","kind":"trial","name":"A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab in endometrial cancer, head and neck squamous cell carcinoma, melanoma and non-small-cell lung cancer, run by GV20 Therapeutics, now recruiting.","summary":"A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies is a phase 1/2 interventional study registered as NCT05669430 by GV20 Therapeutics, with 365 participants planned, started 2023-03-23 and due to reach its primary completion in 2026-12-15. Interventions recorded: GV20-0251 and GV20-0251 and Pembrolizumab [KEYTRUDA®].","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05669430","url":"https://clinicaltrials.gov/study/NCT05669430"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["endometrial","head-and-neck","melanoma","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05669430","phase":"1/2","setting":"An Open-Label Phase 1/2A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Advanced and/or Refractory Solid Tumor Malignancies","sponsor":"GV20 Therapeutics","enrolled":365,"outcomes":[]},"route":"/trials/nct05669430/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}